Long-term symptomatic remission of schizophrenia with once-daily extended release quetiapine fumarate: post-hoc analysis of data from a randomized withdrawal, placebo-controlled study

摘要: Despite available effective medications, many patients with schizophrenia do not become completely symptom free. We report analyses of data from a randomized, double-blind, placebo-controlled relapse prevention study extended release quetiapine fumarate (quetiapine XR) using Remission in Schizophrenia Working Group criteria for symptomatic remission. During 16-week open-label stabilization, stable were switched their current antipsychotic to XR (400, 600 or 800 mg/day flexibly dosed). One hundred and ninety-seven randomized either placebo (planned 1 year until relapse). The was terminated early because the planned interim analysis showed be statistically superior primary outcome variable (time eighty 195 (92.3%) an Positive Negative Syndrome Scale assessment met remission at randomization (following 16 weeks' XR). risk losing significantly higher versus XR: hazard ratio 0.39 (95% confidence interval: 0.19-0.81, P=0.009), that is, 61% reduction XR-treated placebo-treated patients. At 6 months postrandomization, probability would 76% 52% placebo. Once-daily preserving longer-term treatment schizophrenia.